Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes

AIMS: This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes. MATERIALS AND METHODS: This was a prospective, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Irace, Concetta, Cutruzzolà, Antonio, Nuzzi, Annamaria, Assaloni, Roberta, Brunato, Barbara, Pitocco, Dario, Tartaglione, Linda, Di Molfetta, Sergio, Cignarelli, Angelo, Laviola, Luigi, Citro, Giuseppe, Lovati, Elisabetta, Gnasso, Agostino, Tweden, Katherine S, Kaufman, Francine R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317779/
https://www.ncbi.nlm.nih.gov/pubmed/32037699
http://dx.doi.org/10.1111/dom.13993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317779/
https://www.ncbi.nlm.nih.gov/pubmed/32037699
http://dx.doi.org/10.1111/dom.13993

Ejemplares similares